[Endothelial dysfunction in osteoarthrosis patients: changes in response to teraflex treatment].
OBJECTIVE
To investigate severity of endothelial damage and its function in osteoarthrosis patients, changes in endothelial dysfunction in response to teraflex treatment.


METHODS
Eighty patients with manifest gonarthrosis of stage I-II participated in the trial. They received teraflex for 3 months. Treatment efficacy was estimated by Leken's index, pain in the joints, need in analgetics, treatment efficacy in the opinion of the doctor and patient. Endothelial function was assessed by changes in antithrombogenic properties of vascular walls (anticoagulatory and fibrinolytic activity of the vascular wall), in activity of Willebrand factor, circulating endothelial cells. Examination was made before the treatment, after 1 and 3 months of therapy.


RESULTS
A positive effect of teraflex manifested with a significant regress of the Lekken's index, pain syndrome, need in nonsteroidal anti-inflammatory drugs, relief of endothelial damage, improvement of antithrombogenic activity of vascular wall.


CONCLUSIONS
Teraflex has a manifest symptom-modifying effect, good tolerance, reduces endothelial damage.
Rebrov
A P
AP
Kharitonova
I A
IA
D000328:Adult; D000368:Aged; D002809:Chondroitin Sulfates / Q000008:administration & dosage / Q000627:therapeutic use*; D004338:Drug Combinations; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000503:physiopathology; D005260:Female; D005944:Glucosamine / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D020370:Osteoarthritis, Knee / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D016059:Range of Motion, Articular / Q000187:drug effects; D012720:Severity of Illness Index; D016896:Treatment Outcome
D004338:Drug Combinations; D002809:Chondroitin Sulfates; D005944:Glucosamine